US regulatory status: approved.
pharma · Recurrent Respiratory Tract Infections · Actinic Keratosis on the Face or Scalp
ALMIRALL S.P.A
Almirall, S.A.
ALMIRALL S.P.A drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
VIA MESSINA 38, MILANO, Mi 20154, IT, Barcelona HQ
2 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- VIA MESSINA 38, MILANO, Mi 20154, IT, Barcelona
- Employees
- 2
- Programs
- 11
- Drugs
- 20
- Patents
- 308
ALMIRALL S.P.A pipeline
Portfolio lens on 20 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ALMIRALL S.P.A drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to ALMIRALL S.P.A in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to ALMIRALL S.P.A in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
lebrikizumab
Dermatologicals (D11)Dermatologicals (D11) compound in ALMIRALL S.P.A's portfolio. Molecular target: Interleukin-13.
- Target
- Interleukin-13
- Mechanism
- Interleukin-13 inhibitor
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved. Molecular target: Tyrosinase.
- Target
- Tyrosinase
- Mechanism
- Tyrosinase inhibitor
-
Development asset linked to ALMIRALL S.P.A in public FDA and regional records.
-
Development asset linked to ALMIRALL S.P.A in public FDA and regional records.
-
Development asset linked to ALMIRALL S.P.A in public FDA and regional records.
-
retapamulin
Dermatologicals (D06)US regulatory status: approved. Molecular target: 70S ribosome.
- Target
- 70S ribosome
- Mechanism
- 70S ribosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved.
-
Development asset linked to ALMIRALL S.P.A in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
-
tirbanibulin
Dermatologicals (D06)US regulatory status: approved. Molecular target: Proto-oncogene tyrosine-protein kinase Src.
- Target
- Proto-oncogene tyrosine-protein kinase Src
- Mechanism
- Tyrosine-protein kinase SRC inhibitor